Anne May receives 4 million euro for the PREFERABLE project
The so-called PREFERABLE project is granted EUR 4 million by the European innovation program Horizon 2020. This project seeks to determine whether patients with metastatic breast cancer experience fewer side effects of their therapy and whether their quality of life improves if they remain physically active.
Under the leadership of researcher Anne May, PhD, the effectiveness and cost effectiveness of an exercise program is studied in five countries. In these countries, research is also being carried out into the preferences women with breast cancer have in such a program and how an exercise program can be introduced into the various European healthcare systems. PREFERABLE is a collaboration between the UMC Utrecht Julius Center and the Netherlands Cancer Institute, and centers in Germany, Sweden, Spain and Australia. Europe Donna, a European patient organization, is also involved.
Horizon 2020 is the European funding program for Research and Innovation in Europe. The €70+ billion program runs from 2014 to 2020 and offers opportunities to any organization or entrepreneur engaging in research, technological development and innovation in an international context.